CAS 2169919-21-3

SNDX-5613

CAS: 2169919-21-3

Revumenib (SNDX-5613) is a potent and selective oral inhibitor of menin-KMT2A interaction.Cost-effective and quality-assured.

Formel: C₃₂H₄₇FN₆O₄S

Reinheit: 99.12% - 99.97%

Farbe und Form: Yellow Solid

Molekulargewicht: 630.82

Ref: TM-T12943

SNDX-5613

CAS: 2169919-21-3

SNDX-5613

Formel: C₃₂H₄₇FN₆O₄S

Reinheit: ≥98%

Farbe und Form: Solid

Molekulargewicht: 630.82

Ref: 54-BUP04627

Revumenib

CAS: 2169919-21-3

Formel: C₃₂H₄₇FN₆O₄S

Molekulargewicht: 630.82

Ref: 4Z-R-171001

Revumenib

CAS: 2169919-21-3

N-Ethyl-2-((4-(7-((trans-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide

Formel: C₃₂H₄₇FN₆O₄S

Reinheit: 98%

Molekulargewicht: 630.82

Ref: IN-DG01301059

SNDX-5613

CAS: 2169919-21-3

Revumenib, also known as SNDX-5613, is a potent and selective inhibitor of the interaction between menin and the lysine methyltransferase 2A (KMT2A). In recent studies, it has shown promising results in targeting the epigenetic regulator KMT2A, which seems to be involved in certain leukaemia subtypes.

Formel: C₃₂H₄₇FN₆O₄S

Reinheit: Min. 95%

Molekulargewicht: 630.8 g/mol

Ref: 3D-ULD91921

Revumenib

CAS: 2169919-21-3

Formel: C₃₂H₄₇FN₆O₄S

Molekulargewicht: 630.82

Ref: ST-EA-CP-R68000